[Analysis of indoleamine 2, 3-dioxygenase expression in breast cancer patients with bone metastasis].

Kenichi Sakurai, Shigeru Fujisaki, Saki Nagashima, Tetsuyo Maeda, Masahiko Shibata, Kenshi Gonda, Ryouichi Tomita, Shuhei Suzuki, Yukiko Hara, Katsuhisa Enomoto, Sadao Amano

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

We evaluated the clinical significance of indoleamine 2, 3-dioxygenase (IDO) expression in breast cancer patients with bone metastasis. IDO activity can be measured by the tryptophan(Trp)/kynurenine(Kyn) ratio. Trp and Kyn levels were measured by high-performance liquid chromatography (HPLC). The serum IDO levels of postoperative breast cancer patients with a high number of bone metastases were lower than those of patients with a single metastasis lesion. In addition, IDO activity increased in the cases in which the number of metastatic lesions to the bone increased. These results suggest that the expression of IDO in breast cancer patients with bone metastasis may play a critical role in immunosuppression in these patients.

Original languageEnglish
Pages (from-to)1776-1778
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume39
Issue number12
Publication statusPublished - Nov 2012

Fingerprint

Dive into the research topics of '[Analysis of indoleamine 2, 3-dioxygenase expression in breast cancer patients with bone metastasis].'. Together they form a unique fingerprint.

Cite this